Price gouging first drew the biotech sector into the spotlight last month, but now a potential scandal that has been labeled the 2nd Enron has brought the industry under even more scrutiny. Once the darling of the investing world, the fun may be over for the biotech sector as lawmakers seek to reign in the industry.
Biotech’s Surge to the Top
Biotech as a whole has been on a meteoric rise in the past decade as cheap capital, heavy merger and acquisition activity, and incredible innovation produce record profits.
